Treatment of patients with hepatitis C virus on the waiting list
Open Access
- 30 November 2003
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Liver Transplantation
- Vol. 9 (11), S90-S94
- https://doi.org/10.1053/jlts.2003.50247
Abstract
Key points 1. Over 90% of patients with hepatitis C on the waiting list might be candidates for therapy with interferon plus ribavirin. 2. One must exercise caution in the treatment of these patients. Those with Child-Turcotte-Pugh score >11 or Model for End-Stage Liver Disease score >25 should be excluded from treatment. 3. Sustained virologic response (hepatitis C virus RNA-negative) is mainly dependent on viral genotype, with 50% of genotype 2 and 3 patients achieving sustained virologic response. 4. The ability to achieve sustained virologic response in genotype 1 patients is dependent on dose and duration of treatment. 5. Patients rendered hepatitis C virus RNA-negative pretransplantation may not experience posttransplantation recurrence.Keywords
This publication has 14 references indexed in Scilit:
- Natural history of recurrent hepatitis CLiver Transplantation, 2002
- Intracellular pathways mediating estrogen-induced cholangiocyte proliferation in the ratHepatology, 2002
- Peginterferon alfa-2A (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV doseJournal of Hepatology, 2002
- Adult-to-Adult Transplantation of the Right Hepatic Lobe from a Living DonorNew England Journal of Medicine, 2002
- A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus–infected patients awaiting liver transplantationLiver Transplantation, 2002
- Evaluation of 100 patients for living donorliver transplantationLiver Transplantation, 2000
- The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994New England Journal of Medicine, 1999
- The Treatment of Chronic Viral HepatitisNew England Journal of Medicine, 1997
- Recombinant Interferon Alfa Therapy for Chronic Hepatitis CNew England Journal of Medicine, 1989
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaNew England Journal of Medicine, 1989